^
    9ms
    The Janus kinase 2 (JAK2) Mutation Burden is Related to Hematological Outcomes in Thai Patients with Myeloproliferative Neoplasms. (PubMed, Asian Pac J Cancer Prev)
    The allele burden of JAK2 V617F was significantly lower in ET than in PV and PMF. Only the WBC, Hct and Plt counts were significantly different among the JAK2 V617F allele burden subgroups. Measuring the JAK2 V617F allele burden quantitatively might be an additional tool for predicting the hematological outcomes of MPNs.
    Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • JAK2 (Janus kinase 2)
    |
    Ipsogen JAK2 RGQ PCR Kit
    3years
    QIAGEN gains CE-marking for in-vitro diagnostic kit and its automated testing platform NeuMoDx under new EU IVDR framework (Qiagen Press Release)
    "QIAGEN N.V...today announced the certification of its leading in-vitro diagnostic (IVD) kit and its fully automated NeuMoDx platforms under the European Union’s new In-Vitro Diagnostic Medical Devices Regulation (IVDR) replacing the previous IVDD rules since May. The ipsogen JAK2 RGQ PCR Kit used for myeloproliferative neoplasms (MPN), a certain type of blood cancer, is now QIAGEN’s first IVD kit with IVDR CE-marking under Class C."
    European regulatory
    |
    Ipsogen JAK2 RGQ PCR Kit